Cardiogenic shock: A cardiac emergency requires cardiac leadership

Jorge Ferreira Ricardo Fontes Carvalho

PII: \$0870-2551(25)00345-2

DOI: https://doi.org/doi:10.1016/j.repc.2025.11.004

Reference: REPC 2508

To appear in: Revista Portuguesa de Cardiologia

Received Date: 4 November 2025
Accepted Date: 6 November 2025

Please cite this article as: Ferreira J, Carvalho RF, Cardiogenic shock: A cardiac emergency requires cardiac leadership, *Revista Portuguesa de Cardiologia* (2025), doi: https://doi.org/10.1016/j.repc.2025.11.004

This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability. This version will undergo additional copyediting, typesetting and review before it is published in its final form. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article. Please note that Elsevier's sharing policy for the Published Journal Article applies to this version, see: https://www.elsevier.com/about/policies-and-standards/sharing#4-published-journal-article. Please also note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2025 Published by Elsevier España, S.L.U. on behalf of Sociedade Portuguesa de Cardiologia.

Title: Cardiogenic shock: A cardiac emergency requires cardiac leadership

Título: Choque cardiogénico: uma emergência cardíaca que requer liderança da cardiologia

Jorge Ferreira^{1*}, Ricardo Fontes Carvalho^{2,3}

- 1. Serviço de Cardiologia, Hospital de Santa Cruz, Unidade Local de Saúde de Lisboa Ocidental, Carnaxide, Portugal.
- 2. Departamento de Cardiologia-Unidade Local de Saúde Gaia e Espinho, Vila Nova de Gaia, Portugal.
- 3. RISE-Health, Departamento de Cirurgia e Fisiologia, Faculdade de Medicina, Universidade do Porto, Porto, Portugal.

E-mail address: jorge_ferreira@netcabo.pt (J. Ferreira)

Cardiogenic shock (CS) is a life-threatening condition that carries persistently high mortality, despite advances in supportive therapies. The growing use of extracorporeal membrane oxygenation (ECMO), especially in hospitals lacking specialized cardiac intensive care, is transforming CS management. Although increased access to mechanical circulatory support (MCS) offers new opportunities, it highlights important concerns: the need for rigorous clinical oversight, thoughtful patient selection, and optimal timing in this complex, time-sensitive syndrome.

In recent years, the use of ECMO by non-cardiac intensivists has grown, particularly as a rescue strategy or in intensive care units where veno-venous (VV) ECMO programs have been adapted for veno-arterial (VA) support. This change has been largely driven by the rapid expansion of VV-ECMO capacity during the COVID-19 pandemic. Many centers have now repurposed these resources for VA-ECMO—often in cases of CS—without integrated cardiology involvement. Consequently, VA-ECMO is increasingly being initiated by non-cardiology intensivists, sometimes in settings lacking timely access to coronary revascularization or invasive hemodynamic monitoring.

This development is concerning, given that recent randomized controlled trials consistently fail to show a mortality benefit for VA-ECMO in CS. The ECLS-SHOCK trial (Thiele et al.) (1), the largest to date, found no improvement in 30-day mortality with early VA-ECMO compared to standard care in infarct-related CS. Similarly, Ostadal et al. (2) reported no survival advantage with early ECMO initiation in patients with rapidly deteriorating or severe CS. These findings are reinforced by an individual patient data meta-analysis of four randomized trials (3), which concluded that VA-ECMO did not reduce 30-day mortality. It was also associated with increased rates of major bleeding and vascular complications.

^{*}Corresponding Author:

The growing gap between clinical practice and the current evidence base underscores a critical issue: CS is not only a hemodynamic emergency—it is a complex cardiac emergency. Effective management often requires timely revascularization, detailed interpretation of comprehensive cardiac imaging and invasive hemodynamics, and thoughtful selection of targeted MCS devices such as microaxial flow pump, intraaortic balloon counterpulsation, or VA-ECMO. These complex decisions are best made by cardiology-led multidisciplinary teams with specialized skills in cardiac imaging, interventional cardiology, heart surgery, advanced heart failure, and electrophysiology.

Consensus statements from leading cardiology societies support the implementation of structured shock team models, centered in cardiac intensive care units (4,5). These multidisciplinary models have been associated with improved outcomes by standardizing triage, enabling rapid revascularization in infarct-related CS, and guiding stepwise MCS escalation tailored to each patient's underlying condition and hemodynamic profile. In this context, the active involvement of cardiologists is not optional—it is essential to delivering timely, evidence-based care in CS.

Organizational models for advanced intensive cardiac care must prioritize the optimization of care through hyperspecialized cardiology teams (6), as generalist approaches, even when supported by advanced technologies, are insufficient. Delivering this level of care requires the highest standards. Young cardiologists must be encouraged to embrace this fascinating and demanding field, but for their expertise to be fully exercised, adequate structural support is essential.

We call for healthcare systems and policymakers to:

- Recognize that VA-ECMO alone is not a solution to CS;
- Require multidisciplinary shock team involvement in all cases of CS requiring MCS;
- Establish cardiac intensive care as a recognized subspecialty.

In summary, effective CS management requires specialized cardiology expertise. Following expert-driven, cardiology-based care models represents the most rational and evidence-informed approach to improving outcomes in this critically ill population.

References:

- Thiele H, Zeymer U, Neumann FJ, et al. Extracorporeal life support in infarct-related cardiogenic shock. N Engl J Med 2023;389(13):1163-1175.
 [doi:10.1056/NEJMoa2307227]
- 2. Ostadal P, Rohac F, Mlcek M, et al. ECLS in acute myocardial infarction complicated by cardiogenic shock: A randomized clinical trial. *Circulation* 2023;149:1623–1632. [doi:10.1161/CIRCULATIONAHA.122.062949]
- 3. Zeymer U, Freund A, Hochadel M, et al. Venoarterial extracorporeal membrane oxygenation in patients with infarct-related cardiogenic shock: an individual patient data meta-analysis of randomised trials. *Lancet* 2023;402:1338-1346. [doi:10.1016/S0140-6736(23)01607-0]
- 4. Thiele H, Ohman EM, de Waha-Thiele S, et al. Management of cardiogenic shock complicating myocardial infarction: an update 2019. *Eur Heart J* 2019 Aug 21;40(32):2671-2683. [doi:10.1093/eurheartj/ehz363]
- Sinha SS, Morrow DA, Kapur NK, et al. 2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on the evaluation and management of cardiogenic shock: A report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2025;85:1618-1641. [doi:10.1016/j.jacc.2025.02.018]
- 6. Monteiro S, Timóteo AT, Caeiro D, et al. Cardiac intensive care in Portugal: The time for change. *Rev Port Cardiol* 2020;39:401-406. [doi:10.1016/j.repc.2020.04.007]